Novel immunogenomic insights of corona virus disease (COVID-19): Available potential immunotherapeutics, current challenges, immune cell recognition and ongoing managerial strategies

Abstract

The emerging Corona virus strain (severe acute respiratory syndrome corona virus-2 (SARS-CoV-2)) harbors intricate in the development of corona virus infection (COVID-19)-induced pneumonia and subsequently ameliorates lung infection. Genome sequence and interventions reveal proximal resemblance of corona virus strain COVID-19 with severe acute respiratory syndrome (SARS), transmittable to bats, suggesting similar primary hosts in the spread of infection. However, potential rapid human-to-human transmission has caused therapeutic challenges in treating a wide range of humans suffering from corona virus all over the world. However, up to now, no direct vaccines or antiviral drugs are available to treat COVID-19. Previously designed antiviral drugs and convalescent plasma are undergoing investigations as treatment for COVID-19 infected patients. Therapeutic challenges with regards to COVID-19 have prompted scientists to develop fruitful remedies to combat the pathogen. In this review, we address the role of current ongoing therapeutic strategies, , and complex mechanisms of adaptive immune system (B and T cells) to respond to viruses. Furthermore, we illustrate the current challenges in the treatment of COVID-19, managerial strategies, and ongoing and future perspectives.